Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3Neoplasm Metastasis 2Prostatic Neoplasms 1Osteoporosis 1Melanoma 1Mastocytosis, Systemic 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 35durvalumab 23atezolizumab 22Nivolumab 20lenvatinib 19tremelimumab 16Specimen Handling 14Magnetic Resonance Spectroscopy 12sintilimab 11pembrolizumab 9Ipilimumab 9tislelizumab 7Sorafenib 7cabozantinib 5X-Rays 5Immunoglobulin G 5Disulfides 5Cyclophosphamide 5regorafenib 4Radiotherapy 4Radiosurgery 4Radiation 4Oxaliplatin 4Immunotherapy 4Ethiodized Oil 4fludarabine 3donafenib 3Surgical Procedures, Operative 3Folfox protocol 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Denosumab × 90 days × Clear all
NCT07537972 2026-04-17

Denosumab Strategy for Liver Cancer With Bone Metastases

Tongji Hospital

Phase 2 Not yet recruiting
50 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡